OKYO Pharma Ltd (OKYO) income statement
OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.11−0.06 (-5.13%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
OKYO Pharma Ltd income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2026
- –
Financial strength
- Current ratio
- 2.43
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 168.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?